Evidence map›Paper›PMID 38174567›Full record

ArticleStroke2024

Baseline Stroke Risk and Efficacy of Dual-Antiplatelet Therapy: A Post Hoc Analysis of the POINT Trial.

Iyas Daghlas, S Claiborne Johnston, J Donald Easton, Anthony S Kim

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stroke, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00991029 (Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke), which is not on this map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00991029 phase3terminatednot on this map

Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial

TypeinterventionalSponsorUniversity of California, San FranciscoRan2010 to 2018Enrolled4,881ConditionsIschemic Attack, TransientArmsClopidogrel, placebo
3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Iyas DaghlasDepartment of Neurology, University of California, San Francisco (I.D., S.C.J., J.D.E., A.S.K.).ORCID 0000-0001-6924-0641
S Claiborne JohnstonDepartment of Neurology, University of California, San Francisco (I.D., S.C.J., J.D.E., A.S.K.).ORCID 0000-0002-2912-0714
J Donald EastonDepartment of Neurology, University of California, San Francisco (I.D., S.C.J., J.D.E., A.S.K.).ORCID 0000-0002-8039-805X
Anthony S KimDepartment of Neurology, University of California, San Francisco (I.D., S.C.J., J.D.E., A.S.K.).ORCID 0000-0002-8095-6517
University of California, San Francisco · USTexas Department of State Health Services · US

Funding

POINT: PLATELET-ORIENTED INHIBITION IN NEW TIAU01NS062835 · NINDS · UNIVERSITY OF TEXAS AT AUSTIN · PI EASTON, J. DONALD, ELM, JORDAN J. · 2009 to 2017
$56.0M
NINDS NIH HHS U01 NS062835
6 · The paper itself

Abstract

backgroundHigh-risk transient ischemic attacks and minor ischemic strokes are followed by a variable risk of ischemic stroke. We aimed to determine how baseline stroke risk modified the efficacy of clopidogrel-aspirin (referred to here as dual-antiplatelet therapy [DAPT]) for transient ischemic attack and minor ischemic stroke.

methodsWe performed an unplanned secondary analysis of the POINT trial (Platelet-Oriented Inhibition in New Transient Ischemic Attack and Minor Ischemic Stroke). We first evaluated the associations of the CHA

resultsA total of 4841 trial participants were included in this analysis, with 2400 participants assigned to treatment with short-term DAPT and 2430 participants to treatment with aspirin and placebo. The dichotomized SPI-II score, but not the CHA

conclusionsStratification by baseline stroke risk identifies a patient subgroup that derives greater absolute benefit from treatment with DAPT. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT00991029.

Indexed as

Ischemic Attack, TransientIschemic StrokeStrokeAspirinClinical Trials as TopicDrug Therapy, CombinationHemorrhageHumansPlatelet Aggregation InhibitorsRisk FactorsTreatment OutcomeAspirinPlatelet Aggregation Inhibitorsaspirinischemic attack, transientplatelet aggregation inhibitorsprecision medicinestroke

Identifiers

PMID38174567
PMCPMC10857750
OpenAlexW4390582455

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.